Changes in baseline T-cell activation markers through week 12 and week 24 according to the linear regression model. a. by Tosi M. Mwakyandile (16408705)

Subjects:

The parameters of gas exchange markedly decreased in maize <i>zmstomagen1/2</i> mutant compared with in wild type (WT). by Juan-Juan Xu (18590868)

Changes in baseline T-cell exhaustion, monocyte activation and platelet activation markers through week 12 and week 24 according to the linear regression model. a. by Tosi M. Mwakyandile (16408705)

Subjects:

Depletion of <i>cyd-1</i> leads to decreased oocyte quality and increased apoptosis without affecting the DNA damage response (DDR). by Umanshi Rautela (20235283)

Most frequently experienced adverse events among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

<i>RTTN</i>-mutated organoids exhibit decreased proliferation and increased cell death at early stages. by Justine Guguin (9088672)

cGAS inhibition decreases ISG RNA in H358 cells. by Lorellin A. Durnell-Bettis (22656332)

Cumulative incidence of mortality and loss to follow-up (LTF) among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Conditional ablation of <i>Ybx1</i> leads to a reduction in cortical progenitor cell pool and a decrease in cortical thickness. by Jian Zhang (1682)

Participants with virologic suppression or failure at week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Socio-demographic and clinical characteristics of HIV-infected treatment-naïve individuals initiating ART. by Tosi M. Mwakyandile (16408705)

Subjects:

Consolidated Standards of Reporting Trials flow diagram for participants in the trial. by Tosi M. Mwakyandile (16408705)

Subjects:

Changes in baseline CD4 count through week 12 and week 24 according to the linear regression model. by Tosi M. Mwakyandile (16408705)

Subjects:

Cumulative incidence of morbidity, loss to follow-up (LTF) and mortality among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Median changes in CD4 count, platelet activation, immune activation, and exhaustion markers from baseline through week 12 and week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Expression of lipid biosynthetic genes is decreased with polyamine depletion. by Yazmin E. Cruz-Pulido (20285238)

Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i> by Razia Rashid Rahil (22772495)

“…<p>(A) Representative images showed calcium deposition (red). …”

S1 File - by Hongyu Li (1332669)

“…Following the overexpression of miRNA 221 in myocardium, there was a marked alleviation of myocardial injury and cardiomyocyte apoptosis and necrosis, significant enhancement of left ventricular systolic function, and marked decrease in the levels of PLB, p-PLB (Ser16), p-PLB (Thr17), caspase 3 and Cyt C, as well as a significant decrease in total calcium levels in myocardium.…”

Proteasomal activity decreases with ApoE4 expression. by Nathan R. Zuniga (20422428)

Anti-SjLLPi1 antibody treatment decreases worm burden in mice 7 days after <i>S. japonicum</i> infection. by Fanyan Chen (3909178)